

## Company Overview

**OncoSec Medical Incorporated** is a biopharmaceutical company developing its investigational immunotherapy, TAVO, for the treatment of cancer. OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeting agents. Clinical studies of TAVO have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec's lead program evaluating TAVO for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate TAVO in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.

## OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer

Jan 7 2019, 8:30 AM EST

## OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors

Dec 21 2018, 8:30 AM EST

## OncoSec Announces Publication of New Research in the Journal Immunity Highlighting the Role of IL-12 in Anti-PD-1 Therapies with TAVO™ Directly Activating TILs in Patients

Dec 18 2018, 8:30 AM EST

## Stock Overview

Symbol	ONCS
Exchange	Nasdaq
Market Cap	46.41m
Last Price	\$0.7195
52-Week	\$0.541 - \$2.21

01/18/2019 04:00 PM EST

## Investor Relations

T: 855-ONCOSEC (855-662-6732)  
[investors@oncosec.com](mailto:investors@oncosec.com)

## OncoSec Medical Incorporated

3565 General Atomics Ct.  
San Diego, CS 92121

24 Main St.  
Pennington, NJ 08534

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.